Mallinckrodt plc
AMEX: MNK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange Arca
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Sigurdur Oli Olafsson
- Employees
- 2,673
- Headquarters
- Dublin, Ireland
- IPO year
- 2022
- Market cap
- $4.5M
- Website
- https://www.mallinckrodt.com
Loading MNK…
Loading profile data…Frequently asked questions about MNK
What does Mallinckrodt plc (MNK) do?
Mallinckrodt plc operates as a global pharmaceutical company, engaged in the development, manufacturing, marketing, and distribution of specialized medical products and therapies. Its extensive reach covers the United States, Europe, the Middle East, Africa, and various other international markets. The firm's business operations are segmented in...
Where does MNK trade?
Mallinckrodt plc (MNK) trades on the New York Stock Exchange Arca.
What sector is MNK in?
Mallinckrodt plc (MNK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Mallinckrodt plc?
Sigurdur Oli Olafsson is the chief executive officer of Mallinckrodt plc (MNK).
Where is Mallinckrodt plc headquartered?
Mallinckrodt plc is headquartered in Ireland.
Does MNK pay a dividend?
Mallinckrodt plc (MNK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MNK go public?
Mallinckrodt plc (MNK) completed its initial public offering in 2022.